Exelixis, Inc.
EXELNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $16.32B
- P/E (TTM)
- 18.96
- Forward P/E
- 13.89
- Dividend yield
- -
- 52-week range
- $33.76$61.66
- Volume (live)
- -
- Avg. volume (3M)
- 2.29M
Exelixis (EXEL) Stock Price & Financial Analysis
Exelixis Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $61.74 - $63.39 |
|---|---|
| 52-Week High | $61.66 |
| 52-Week Low | $33.76 |
| Open | $62.98 |
| Volume (last close) | 2.64M |
| Average Volume (3M) | 2.29M |
| Revenue (TTM) | 2.44B |
|---|---|
| Net Income (TTM) | 860.62M |
| Free Cash Flow (TTM) | 1.16B |
| EPS (TTM) | $3.17 |
| Profit Margin | 35.33% |
| Operating Margin | 40.70% |
| Return on Equity (ROE) | 46.68% |
| Debt to Equity | 0.09 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 16.32B |
|---|---|
| Shares Outstanding | 259.68M |
| P/E Ratio (TTM) | 18.96 |
| Forward P/E | 13.89 |
| Price to Sales (P/S) | 6.70 |
| Price to Book (P/B) | 8.85 |
| EV/EBITDA | 15.63 |
| 50-Day MA | $56.47 |
|---|---|
| 200-Day MA | $49.67 |
| 1-Year Change | +60.08% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Exelixis at a Glance
As of the Oct 16, 2026 close, Exelixis (EXEL) has a market capitalization of $16.32B. The stock trades at 19.0× trailing earnings, 13.9× forward earnings and 6.7× sales. Over the trailing twelve months it earned $860.62M on revenue of $2.44B (a 35.3% profit margin) and generated $1.16B of free cash flow. Revenue grew 9.2% year over year.
As of its latest reported balance sheet, it holds $281.45M in cash and securities against $165.93M of debt, a net cash position of $115.52M.
Exelixis does not currently pay a dividend.
The share price is up 60.1% over the past year. At $62.23 (the Oct 16, 2026 close) it sits near the top of its 52-week range of $33.76 to $61.66, above its 200-day moving average of $49.67.
Based on 15 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $52.45, 15.7% below the Oct 16, 2026 close.
Frequently Asked Questions About Exelixis
What is the current stock price for EXEL?
As of the Oct 16, 2026 close, EXEL stock trades at $62.23. The 52-week range is $33.76–$61.66, with a day range of $61.74–$63.39.
What is the P/E ratio for EXEL?
As of the Oct 16, 2026 close, Exelixis's trailing twelve-month (TTM) P/E ratio is 19.0, meaning investors pay $19.0 for every $1 of annual earnings. The forward P/E is 13.9, reflecting analyst expectations for future earnings. Exelixis operates in the Healthcare sector.
Does EXEL pay dividends?
Exelixis does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for EXEL?
Based on ratings from 15 professional analysts over the last 90 days, the consensus for EXEL is Hold. The average 12-month price target is $52.45, a 15.7% downside from the Oct 16, 2026 close of $62.23.
What is the market cap of EXEL?
As of the Oct 16, 2026 close, Exelixis's market capitalization is $16.16B, classifying it as a large-cap company. Exelixis operates in the Healthcare sector within the Biotechnology industry.